Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price for the company.

Lipocine Stock Down 1.8 %

LPCN stock opened at $4.37 on Friday. The company has a market cap of $23.38 million, a PE ratio of -5.75 and a beta of 1.23. Lipocine has a 52 week low of $3.20 and a 52 week high of $11.79. The business has a 50-day simple moving average of $4.88 and a 200 day simple moving average of $5.02.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. On average, analysts anticipate that Lipocine will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP purchased a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent quarter. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.